Tymvios Charalambos, Jones Sarah, Moore Christopher, Pitchford Simon C, Page Clive P, Emerson Michael
Sir Alexander Fleming Building, National Heart and Lung Institute, Imperial College London, Exhibition Road, London, UK.
Thromb Haemost. 2008 Feb;99(2):435-40. doi: 10.1160/TH07-07-0479.
Identifying and evaluating new therapeutic targets in platelets requires advanced animal models in which platelet responses can be measured directly and in situ. This is important because platelet function is strongly influenced by external factors such as those originating from the vascular endothelium. Our objectives were to record graded, non-lethal thromboembolic platelet responses to platelet agonists in situ in the mouse and to demonstrate an inhibitory effect of aspirin in our model. Radiolabelled platelets were infused into anaesthetized mice and responses to ADP, collagen and thrombin measured as changes in platelet associated counts in miniaturized detection probes placed over the thoracic region. All agonists induced dose-dependent changes in platelet counts due to accumulation of thrombi in the pulmonary vasculature. We confirmed a specific platelet effect by comparing platelet and erythrocyte responses and showing platelet aggregates in the lung vasculature histologically. Simultaneous injection of collagen and adrenaline induced increased and protracted synergistic platelet responses compared with individual injection of these agents and aspirin inhibited collagen-induced responses. We confirmed the clinical relevance of our model by showing that platelet thromboembolism in the mouse, like pulmonary embolism in humans, impaired cardiovascular performance. We present a refined method for measuring platelet agonist dose-responses and thromboembolism in real-time without inducing mortality in the mouse. Our technique will be useful in investigating the molecular determinants of physiological and pathophysiological platelet function in an in-vivo context and will enable investigations of both platelet and non-platelets mediators of thrombus formation.
识别和评估血小板中的新治疗靶点需要先进的动物模型,以便能够直接在原位测量血小板反应。这一点很重要,因为血小板功能受到外部因素的强烈影响,比如那些源自血管内皮的因素。我们的目标是在小鼠原位记录对血小板激动剂的分级、非致死性血栓栓塞性血小板反应,并在我们的模型中证明阿司匹林的抑制作用。将放射性标记的血小板注入麻醉的小鼠体内,并在置于胸部区域的小型检测探针中测量对二磷酸腺苷(ADP)、胶原蛋白和凝血酶的反应,以血小板相关计数的变化来衡量。由于肺血管系统中血栓的积累,所有激动剂均诱导血小板计数出现剂量依赖性变化。我们通过比较血小板和红细胞反应,并在组织学上显示肺血管系统中的血小板聚集体,证实了特定的血小板效应。与单独注射这些药物相比,同时注射胶原蛋白和肾上腺素可诱导增强且持久的协同血小板反应,并且阿司匹林可抑制胶原蛋白诱导的反应。我们通过证明小鼠体内的血小板血栓栓塞与人类的肺栓塞一样会损害心血管功能,证实了我们模型的临床相关性。我们提出了一种改进的方法,用于实时测量血小板激动剂剂量反应和血栓栓塞,而不会导致小鼠死亡。我们的技术将有助于在体内研究生理和病理生理血小板功能的分子决定因素,并能够研究血栓形成的血小板和非血小板介质。